Zacks Research Downgrades Brainsway (NASDAQ:BWAY) to Hold

Brainsway (NASDAQ:BWAY) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Several other research firms have also weighed in on BWAY. BTIG Research raised their price objective on shares of Brainsway from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. New Street Research reissued a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Brainsway in a report on Friday, July 17th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Brainsway in a research report on Tuesday, July 21st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $16.33.

Brainsway Stock Performance

BWAY opened at $16.60 on Tuesday. The company has a market capitalization of $666.16 million, a PE ratio of 47.43 and a beta of 1.24. The stock’s fifty day moving average is $15.08 and its 200-day moving average is $14.33. Brainsway has a one year low of $6.25 and a one year high of $17.40.

Brainsway (NASDAQ:BWAY) last announced its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.04. The business had revenue of $17.11 million during the quarter, compared to analysts’ expectations of $16.54 million. Brainsway had a return on equity of 12.28% and a net margin of 15.68%. On average, equities research analysts forecast that Brainsway will post 0.33 EPS for the current fiscal year.

Institutional Trading of Brainsway

Several institutional investors and hedge funds have recently bought and sold shares of BWAY. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Brainsway in the first quarter worth about $40,000. Ballast Advisors LLC acquired a new stake in shares of Brainsway during the first quarter valued at approximately $55,000. Raymond James Financial Inc. purchased a new stake in shares of Brainsway in the 2nd quarter valued at approximately $85,000. Bank of America Corp DE acquired a new position in Brainsway in the 3rd quarter worth approximately $107,000. Finally, Royal Bank of Canada boosted its stake in Brainsway by 1,145.9% in the 4th quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock worth $160,000 after purchasing an additional 7,735 shares during the period. Institutional investors and hedge funds own 30.11% of the company’s stock.

Key Stories Impacting Brainsway

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Quarterly earnings beat expectations: BrainsWay reported second-quarter EPS of $0.14, versus the $0.10 analyst consensus, while revenue of $17.11 million exceeded estimates of $16.54 million. Revenue increased 35% year over year to a record level, and the company posted a 15.68% net margin. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Revenue guidance was raised or reaffirmed above consensus: Management guided for fiscal 2026 revenue of $68 million to $70 million, compared with the $67.8 million consensus estimate. The outlook supports expectations for continued demand for BrainsWay’s noninvasive deep transcranial magnetic stimulation systems. BrainsWay Earnings Report and Conference Call
• Positive Sentiment: Analyst price target increased: BTIG Research raised its target from $18 to $20 and maintained a Buy rating, implying additional upside based on the referenced $16.60 share price. BrainsWay Price Target Raised by BTIG
• Neutral Sentiment: Momentum is strong, but valuation warrants attention: BWAY is trading near its one-year high and above its 50-day and 200-day moving averages. However, its price-to-earnings ratio of 47.43 leaves the stock sensitive to any slowdown in growth or future earnings disappointments. Brainsway Sets New 1-Year High Following Strong Earnings
• Neutral Sentiment: Reported short interest was listed as zero shares, so the data does not indicate meaningful short-covering pressure or a significant short-interest overhang.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.